Jayesh ranjan, Vice-Chancellor of the Jawaharlal Nehru Technological University, Hyderabad

Hyderabad, Dec 26 Leading pharmaceutical company Hetero on Monday announced that it has received the World Health Organization Prequalification of Medicines Programme (WHO PQ) approval for its generic version of Covid-19 oral antiviral treatment candidate Nirmatrelvir.This is the first pre-qualification for a generic version of Pfizer's Covid-19 oral antiviral drug 'Paxlovid', which the WHO called, the best therapeutic choice for high-risk patients to date.WHO made a strong recommendation for Nirmatrelvir and Ritonavir for mild and moderate Covid-19 patients at highest risk of hospital admission, such as unvaccinated, aged, or immunosuppressed patients, the company saidThe combi pack, launched by Hetero as Nirmacom,will contain nirmatrelvir 150 mg (2 tablets) and ritonavir 100mg (1 tablet). It is available by prescription only and should be initiated as soon as possible after diagnosis of Covid-19 and within five days of symptom onset.Nirmacom will be manufactured at Hetero's facilities in India."WHO Prequalification for NIRMACOM is a significant milestone in the fight against Covid-19 as it allows us to expand access to this important innovative antiretroviral drug to people in need. We are committed to making NIRMACOM available faster at affordable prices across 95 LMICs including India," said Dr. Vamsi Krishna Bandi, Managing Director, Hetero Group of Companies.Hetero entered into a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) for manufacturing and sale of a generic version of Pfizer's Covid-19 oral antiviral treatment candidate Nirmatrelvir, which is co-packaged with Ritonavir in Low and Middle Income Countries (LMICs)."We are delighted to see the first generic version of nirmatrelvir under MPP license with Pfizer, receive quality assurance approval from WHO. This is an impressive achievement from Hetero as we announced the sub-licence agreements just nine months ago. With cases of Covid-19 again on the rise we need to make treatments readily available in LMICs so no one is left behind," said Charles Gore, Executive Director of MPP.Hetero has already received Emergency Use Authorization (EUA) approval from the Drugs Controller General of India (DCGI) to manufacture and market Nirmacom.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Jayesh RanjanFOLLOW

Jayesh ranjan, Latest News

The Subject Expert Committee (SEC) of Central Drugs Standards Control Organisation (CDSCO) on Tuesday recommended the grant of permission ... ...

Hyderabad, Dec 27 Stating that larger participation of women results in better overall development, President Droupadi Murmu on ... ...

Hyderabad, Dec 27 With 19 MBBS seats for one lakh population, Telangana now has the highest ratio of ... ...

Hyderabad, Dec 27 President Droupadi Murmu on Tuesday urged students to read more in order to improve their ... ...

Mr. T. Nagayasu, Chairman & MD, Mr. K. Tanaka, Dy. CEO of Mitsubishi, Mr. M Hasegawa, Dy. GM, Takasago ... ...

Hyderabad, Dec 27 Vaccine maker Bharat Biotech's intranasal vaccine for Covid-19, the first in the world, is scheduled ... ...

Hyderabad, Dec 26 The Directorate of Revenue Intelligence (DRI) has seized about 25 kg of stimulant drug Mephedrone, ... ...

Hyderabad, Dec 26 Leading pharmaceutical company Hetero on Monday announced that it has received the World Health Organization ... ...